secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001104659-23-011184
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium prelim Q4/FY22 revenue at high-end of guidance; announces $175M convertible notes offering
--------------------------------------------------------------------------------

- Prelim FY22 product revenue $460.0M-$462.5M; Q4 $125.7M-$128.2M; both at or above prior guidance high-end.
- Prelim FY22 adjusted EBITDA $261.5M-$264.0M; Q4 adjusted EBITDA $71.9M-$74.4M.
- Announced $175M convertible senior notes due 2029, with $26.25M greenshoe option to initial purchaser.
- Intends to use part of proceeds to repurchase portion of its 2.625% 2026 convertible notes in private transactions.
- Remaining proceeds for general corporate purposes including business development, debt repayment, and shareholder returns.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/tm235588d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-011184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer